Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Artificial Intelligence & Technology ETF (AIQ) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Global X Artificial Intelligence & Technology ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Global X Artificial Intelligence & Technology ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Global X Artificial Intelligence & Technology ETF trades at $63.79. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.

ACADAIQ
Market Cap
$5.07B
Sector
HealthSector/Thematic
52-Week High
$29.41$70.14
52-Week Low
$20.06$43.88
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

Global X Artificial Intelligence & Technology ETF

AIQ, the Global X Artificial Intelligence & Technology ETF, trades at $63.79, up 0.44% on the day, with a bullish technical signal driven by moving averages. The ETF has gained attention for outperforming broader indices, with recent news highlighting its 25% gain and positioning in the AI sector. Key resistance lies at $64, while support is near $63.

The outlook remains positive due to strong momentum in AI investments, but risks include sector volatility and high valuations. Analyst sentiment is generally optimistic, with the ETF seen as a diversified play on AI growth, though the absence of dividend income and fee considerations may weigh on long-term returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ